Drug Information



Brand Name:ProleukinTrade Name:Aldesleukin
FDA Approved For:Adults with metastatic renal cell carcinoma (metastatic RCC). PROLEUKIN is indicated for the treatment of adults with metastatic melanoma.Pediatric Use:
Manufacturer and/or Distributor:Chiron Corp

Adverse Reactions:

The rate of drug-related deaths in the 255 metastatic RCC patients who received single-agent PROLEUKIN (aldesleukin) was 4% (11/255); the rate of drug-related deaths in the 270 metastatic melanoma patients who received single-agent PROLEUKIN was 2% (6/270)… The following life-threatening (grade 4) events were reported by <1% of the 525 patients: hypothermia; shock; bradycardia; ventricular extrasystoles; myocardial ischemia; syncope; hemorrhage; atrial arrhythmia; phlebitis; AV block second degree; endocarditis; pericardial effusion; peripheral gangrene; thrombosis; coronary artery disorder; stomatitis; nausea and vomiting; liver function tests abnormal; gastrointestinal hemorrhage; hematemesis; bloody diarrhea; gastrointestinal disorder; intestinal perforation; pancreatitis; anemia; leukopenia; leukocytosis; hypocalcemia; alkaline phosphatase increase; BUN increase; hyperuricemia; NPN increase; respiratory acidosis; somnolence; )